Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Blood Specimen Collection 7Drug Therapy 6Surveys and Questionnaires 5Radiotherapy 5Radiosurgery 5Docetaxel 5Therapeutics 4Specimen Handling 4Immunotherapy 4Hepatectomy 4exemestane 3enzalutamide 3apalutamide 3Trastuzumab 3Hematologic Tests 3Data Collection 3Biopsy 3Biological Assay 3Anastrozole 3Abiraterone Acetate 3trastuzumab deruxtecan 2palbociclib 2darolutamide 2abiraterone 2abemaciclib 2Wearable Electronic Devices 2Triptorelin Pamoate 2Tamoxifen 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasm Metastasis × Combined Modality Therapy × Clear all
NCT06993506 2025-05-29

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
500 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡